These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 19469696)

  • 1. Impact of psychotic relapse definitions in assessing drug efficacy and costs: comparison of quetiapine XR, olanzapine and paliperidone ER.
    Knapp M; Locklear J; Järbrink K
    Curr Med Res Opin; 2009 Jul; 25(7):1593-603. PubMed ID: 19469696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia.
    Canuso CM; Dirks B; Carothers J; Kosik-Gonzalez C; Bossie CA; Zhu Y; Damaraju CV; Kalali AH; Mahmoud R
    Am J Psychiatry; 2009 Jun; 166(6):691-701. PubMed ID: 19411369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial.
    Liebowitz M; Lam RW; Lepola U; Datto C; Sweitzer D; Eriksson H
    Depress Anxiety; 2010 Oct; 27(10):964-76. PubMed ID: 20734365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial.
    Schreiner A; Niehaus D; Shuriquie NA; Aadamsoo K; Korcsog P; Salinas R; Theodoropoulou P; Fernández LG; Uçok A; Tessier C; Bergmans P; Hoeben D
    J Clin Psychopharmacol; 2012 Aug; 32(4):449-57. PubMed ID: 22722501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Annual cost of relapses and relapse-related hospitalizations in adults with schizophrenia: results from a 12-month, double-blind, comparative study of lurasidone vs quetiapine extended-release.
    Rajagopalan K; O'Day K; Meyer K; Pikalov A; Loebel A
    J Med Econ; 2013 Aug; 16(8):987-96. PubMed ID: 23742620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of paliperidone extended release in Spain.
    Treur M; Baca E; Bobes J; Cañas F; Salvador L; Gonzalez B; Heeg B
    J Med Econ; 2012; 15 Suppl 1():26-34. PubMed ID: 23016569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder.
    Vieta E; Nuamah IF; Lim P; Yuen EC; Palumbo JM; Hough DW; Berwaerts J
    Bipolar Disord; 2010 May; 12(3):230-43. PubMed ID: 20565430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
    Fowler JA; Bettinger TL; Argo TR
    Clin Ther; 2008 Feb; 30(2):231-48. PubMed ID: 18343262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resource utilization and costs of schizophrenia patients treated with olanzapine versus quetiapine in a Medicaid population.
    Yu AP; Atanasov P; Ben-Hamadi R; Birnbaum H; Stensland MD; Philips G
    Value Health; 2009; 12(5):708-15. PubMed ID: 19508658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended-release quetiapine fumarate (quetiapine XR) versus risperidone in the treatment of depressive symptoms in patients with schizoaffective disorder or schizophrenia: a randomized, open-label, parallel-group, flexible-dose study.
    Di Fiorino M; Montagnani G; Trespi G; Kasper S
    Int Clin Psychopharmacol; 2014 May; 29(3):166-76. PubMed ID: 24681810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.
    Mladsi DM; Grogg AL; Irish WD; Lopez RB; Degen K; Swann A; Nimsch CT
    Curr Med Res Opin; 2004 Dec; 20(12):1883-93. PubMed ID: 15701206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paliperidone extended release: a review of its use in the management of schizophrenia.
    Chwieduk CM; Keating GM
    Drugs; 2010 Jul; 70(10):1295-317. PubMed ID: 20568835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.
    Kane J; Canas F; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M
    Schizophr Res; 2007 Feb; 90(1-3):147-61. PubMed ID: 17092691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: a randomized, double-blind, placebo-controlled study.
    Hough DW; Natarajan J; Vandebosch A; Rossenu S; Kramer M; Eerdekens M
    Int Clin Psychopharmacol; 2011 Jan; 26(1):25-34. PubMed ID: 20881844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of extended-release quetiapine fumarate on hospitalization length and cost in schizophrenia and bipolar disorder patients: a retrospective, hospital-based, US-cohort analysis.
    Locklear JC; Wahlqvist P; Gustafsson U; Udd M; Fajutrao L; Eriksson H
    J Comp Eff Res; 2014 Jul; 3(4):335-44. PubMed ID: 25275231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode.
    Berwaerts J; Melkote R; Nuamah I; Lim P
    J Affect Disord; 2012 May; 138(3):247-58. PubMed ID: 22377512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients.
    Hu S; Yao M; Peterson BS; Xu D; Hu J; Tang J; Fan B; Liao Z; Yuan T; Li Y; Yue W; Wei N; Zhou W; Huang M; Xu Y
    Psychopharmacology (Berl); 2013 Nov; 230(1):3-13. PubMed ID: 23559220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of once-daily quetiapine extended release in patients with schizophrenia switched from other antipsychotics: an open-label study in Chinese population.
    Pan PY; Lee MS; Yeh CB
    BMC Psychiatry; 2015 Jan; 15():1. PubMed ID: 25609320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paliperidone extended release.
    Yang LP; Plosker GL
    CNS Drugs; 2007; 21(5):417-25; discussion 426-7. PubMed ID: 17447829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.